The whole world of gambling is on your smartphone with the Mostbet app - join us!
Home  »  Companies   »  Standard BioTools Inc. (LAB) Stock: A Closer Look ...

Standard BioTools Inc. (LAB) Stock: A Closer Look at the Market Potential

while the 36-month beta value is 1.42.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The average price point forecasted by analysts for Standard BioTools Inc. (LAB) is $4.00, which is $1.17 above the current market price. The public float for LAB is 76.78M, and currently, short sellers hold a 3.33% ratio of that floaft. The average trading volume of LAB on September 19, 2023 was 239.50K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


LAB) stock’s latest price update

Standard BioTools Inc. (NASDAQ: LAB)’s stock price has increased by 6.79 compared to its previous closing price of 2.65. However, the company has seen a -1.05% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-07-25 that SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2023 financial results on Tuesday, August 8, 2023, after the close of the market.

LAB’s Market Performance

Standard BioTools Inc. (LAB) has seen a -1.05% fall in stock performance for the week, with a 5.20% gain in the past month and a 40.80% surge in the past quarter. The volatility ratio for the week is 5.15%, and the volatility levels for the past 30 days are at 5.71% for LAB. The simple moving average for the last 20 days is 0.27% for LAB stock, with a simple moving average of 37.09% for the last 200 days.

Analysts’ Opinion of LAB

Many brokerage firms have already submitted their reports for LAB stocks, with KeyBanc Capital Markets repeating the rating for LAB by listing it as a “Overweight.” The predicted price for LAB in the upcoming period, according to KeyBanc Capital Markets is $4 based on the research report published on July 12, 2023 of the current year 2023.

LAB Trading at 7.65% from the 50-Day Moving Average

After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.44% of loss for the given period.

Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 5.15%, as shares surge +4.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.08% upper at present.

During the last 5 trading sessions, LAB fell by -2.13%, which changed the moving average for the period of 200-days by +101.37% in comparison to the 20-day moving average, which settled at $2.83. In addition, Standard BioTools Inc. saw 141.88% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at LAB starting from Casdin Eli, who purchase 800,000 shares at the price of $2.29 back on May 19. After this action, Casdin Eli now owns 1,200,000 shares of Standard BioTools Inc., valued at $1,835,920 using the latest closing price.

Casdin Partners Master Fund, L, the Director of Standard BioTools Inc., purchase 800,000 shares at $2.29 during a trade that took place back on May 19, which means that Casdin Partners Master Fund, L is holding 1,200,000 shares at $1,835,920 based on the most recent closing price.

Stock Fundamentals for LAB

Current profitability levels for the company are sitting at:

  • -115.07 for the present operating margin
  • +37.83 for the gross margin

The net margin for Standard BioTools Inc. stands at -194.08. The total capital return value is set at -41.84, while invested capital returns managed to touch -72.69. Equity return is now at value 94.90, with -22.00 for asset returns.

Based on Standard BioTools Inc. (LAB), the company’s capital structure generated 44.67 points at debt to equity in total, while total debt to capital is 30.88.

When we switch over and look at the enterprise to sales, we see a ratio of 1.39, with the company’s debt to enterprise value settled at 0.30. The receivables turnover for the company is 5.50 and the total asset turnover is 0.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.81.


In a nutshell, Standard BioTools Inc. (LAB) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Should You Invest in BP p.l.c. (BP) Now?

BP p.l.c. (NYSE: BP) has a higher price-to-earnings ratio of 5.78x compared to its average ratio, and the 36-month beta value for BP is at